Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 47

    2.

    A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.

    Kobayashi T, Koizumi T, Agatsuma T, Yasuo M, Tsushima K, Kubo K, Eda S, Kuraishi H, Koyama S, Hachiya T, Ohura N.

    Cancer Chemother Pharmacol. 2012 May;69(5):1241-6. Epub 2012 Jan 26.

    PMID:
    22278730
    [PubMed - in process]
    3.

    Phase I and pharmacologic study of weekly amrubicin in patients with refractory or relapsed lung cancer: Central Japan Lung Study Group (CJLSG) 0601 trial.

    Kitagawa C, Saka H, Kajikawa S, Mori K, Oki M, Suzuki R.

    Cancer Chemother Pharmacol. 2012 May;69(5):1379-85. Epub 2012 Jan 12.

    PMID:
    22237957
    [PubMed - in process]
    4.

    Pharmacokinetics of carboplatin in a hemodialysis patient with small-cell lung cancer.

    Hiraike M, Hiraki Y, Misumi N, Hanada K, Tsuji Y, Kamimura H, Karube Y, Kashiwabara K.

    Cancer Chemother Pharmacol. 2012 Mar;69(3):845-8. Epub 2011 Dec 23.

    PMID:
    22194156
    [PubMed - indexed for MEDLINE]
    5.

    CIP-13F, a novel aminopeptidase N (APN/CD13) inhibitor, inhibits Lewis lung carcinoma growth and metastasis in mice.

    Pei KL, Yuan Y, Qin SH, Wang Y, Zhou L, Zhang HL, Qu XJ, Cui SX.

    Cancer Chemother Pharmacol. 2012 Apr;69(4):1029-38. Epub 2011 Dec 21.

    PMID:
    22186885
    [PubMed - in process]
    6.

    Phase II study of S-1 monotherapy in patients with previously treated, advanced non-small-cell lung cancer.

    Wada M, Yamamoto M, Ryuge S, Nagashima Y, Hayashi N, Maki S, Otani S, Katono K, Takakura A, Yanaihara T, Igawa S, Yokoba M, Mitsufuji H, Kubota M, Katagiri M, Masuda N.

    Cancer Chemother Pharmacol. 2012 Apr;69(4):1005-11. Epub 2011 Dec 8.

    PMID:
    22160350
    [PubMed - in process]
    7.

    Intratumor heterogeneity and chemotherapy-induced changes in EGFR status in non-small cell lung cancer.

    Jakobsen JN, Sørensen JB.

    Cancer Chemother Pharmacol. 2012 Feb;69(2):289-99. Epub 2011 Dec 1. Review.

    PMID:
    22130585
    [PubMed - indexed for MEDLINE]
    8.

    Preclinical evaluation of the novel multi-targeted agent R1530.

    Kolinsky K, Tovar C, Zhang YE, Railkar A, Yang H, Carvajal D, Nevins T, Geng W, Linn M, Packman K, Liu JJ, Zhang Z, Wovkulich P, Ju G, Higgins B.

    Cancer Chemother Pharmacol. 2011 Dec;68(6):1585-94. Epub 2011 May 8.

    PMID:
    21553286
    [PubMed - indexed for MEDLINE]
    9.

    Comparison of different semi-mechanistic models for chemotherapy-related neutropenia: application to BI 2536 a Plk-1 inhibitor.

    Soto E, Staab A, Doege C, Freiwald M, Munzert G, Trocóniz IF.

    Cancer Chemother Pharmacol. 2011 Dec;68(6):1517-27. Epub 2011 Apr 24.

    PMID:
    21516508
    [PubMed - indexed for MEDLINE]
    10.

    Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4).

    Murakami H, Tamura T, Takahashi T, Nokihara H, Naito T, Nakamura Y, Nishio K, Seki Y, Sarashina A, Shahidi M, Yamamoto N.

    Cancer Chemother Pharmacol. 2012 Apr;69(4):891-9. Epub 2011 Nov 10.

    PMID:
    22071596
    [PubMed - in process]
    11.

    The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer.

    Wakelee HA, Takimoto CH, Lopez-Anaya A, Chu Q, Middleton G, Dunlop D, Ramlau R, Leighl N, Rowinsky EK, Hao D, Zatloukal P, Jacobs CD, Rodon J.

    Cancer Chemother Pharmacol. 2012 Feb;69(2):563-71. Epub 2011 Nov 6.

    PMID:
    22057855
    [PubMed - indexed for MEDLINE]
    12.

    A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC).

    Wakelee HA, Middleton G, Dunlop D, Ramlau R, Leighl N, Hao D, Lopez-Anaya A, Zatloukal P, Jacobs CD.

    Cancer Chemother Pharmacol. 2012 Mar;69(3):815-24. Epub 2011 Nov 6.

    PMID:
    22057854
    [PubMed - indexed for MEDLINE]
    13.

    A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC).

    Rodon J, Jacobs CD, Chu Q, Rowinsky EK, Lopez-Anaya A, Takimoto CH, Wakelee HA.

    Cancer Chemother Pharmacol. 2012 Mar;69(3):825-34. Epub 2011 Nov 6.

    PMID:
    22057853
    [PubMed - indexed for MEDLINE]
    14.

    Pharmacokinetic and pharmacodynamic study on amrubicin and amrubicinol in Japanese patients with lung cancer.

    Makino Y, Yamamoto N, Sato H, Ando R, Goto Y, Tanai C, Asahina H, Nokihara H, Sekine I, Kunitoh H, Ohe Y, Sugiyama E, Yokote N, Tamura T, Yamamoto H.

    Cancer Chemother Pharmacol. 2012 Apr;69(4):861-9. Epub 2011 Nov 1.

    PMID:
    22042514
    [PubMed - in process]
    15.

    A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer.

    Chow LQ, Blais N, Jonker DJ, Laurie SA, Diab SG, Canil C, McWilliam M, Thall A, Ruiz-Garcia A, Zhang K, Tye L, Chao RC, Camidge DR.

    Cancer Chemother Pharmacol. 2012 Mar;69(3):709-22. Epub 2011 Oct 12.

    PMID:
    21989766
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    16.

    Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight.

    Min JH, Lee HY, Lim H, Ahn MJ, Park K, Chung MP, Lee KS.

    Cancer Chemother Pharmacol. 2011 Nov;68(5):1099-109. Epub 2011 Sep 13. Review.

    PMID:
    21913033
    [PubMed - indexed for MEDLINE]
    17.

    Pharmacokinetics of aprepitant and dexamethasone after administration of chemotherapeutic agents and effects of plasma substance P concentration on chemotherapy-induced nausea and vomiting in Japanese cancer patients.

    Takahashi T, Nakamura Y, Tsuya A, Murakami H, Endo M, Yamamoto N.

    Cancer Chemother Pharmacol. 2011 Sep;68(3):653-9. Epub 2010 Dec 2.

    PMID:
    21125277
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    18.

    A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer.

    Grossi F, de Marinis F, Gebbia V, Riccardi F, Caffo O, Gamucci T, Ferraù F, Nardi M, Moscetti L, Boni L, Dondi D, Galligioni E.

    Cancer Chemother Pharmacol. 2012 Feb;69(2):369-75. Epub 2011 Jul 21.

    PMID:
    21833588
    [PubMed - indexed for MEDLINE]
    19.

    Cryptotanshinone has diverse effects on cell cycle events in melanoma cell lines with different metastatic capacity.

    Chen L, Zheng SZ, Sun ZG, Wang AY, Huang CH, Punchard NA, Huang SL, Gao X, Lu Y.

    Cancer Chemother Pharmacol. 2011 Jul;68(1):17-27. Epub 2010 Sep 4.

    PMID:
    20820782
    [PubMed - indexed for MEDLINE]
    20.

    Phase II study of combined belotecan and cisplatin as first-line chemotherapy in patients with extensive disease of small cell lung cancer.

    Hong J, Jung M, Kim YJ, Sym SJ, Kyung SY, Park J, Lee SP, Park JW, Cho EK, Jeong SH, Shin DB, Lee JH.

    Cancer Chemother Pharmacol. 2012 Jan;69(1):215-20. Epub 2011 Jun 21.

    PMID:
    21691745
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk